Simple model for estimation of absorbed dose by organs and tumors after PRRT from a single SPECT/CT study.
Journal
EJNMMI physics
ISSN: 2197-7364
Titre abrégé: EJNMMI Phys
Pays: Germany
ID NLM: 101658952
Informations de publication
Date de publication:
26 Aug 2021
26 Aug 2021
Historique:
received:
05
04
2021
accepted:
10
08
2021
entrez:
26
8
2021
pubmed:
27
8
2021
medline:
27
8
2021
Statut:
epublish
Résumé
Following each cycle of peptide receptor radionuclide therapy (PRRT), absorbed doses by tumors and normal organs are typically calculated from three quantitative single-photon emission computed tomography (SPECT)/computed tomography (CT) studies acquired at t There was no difference in management decisions, whether PRRT can be safely continued or not because unsafe absorbed dose to risk organs between the standard and the MLR model-based protocol using a single SPECT/CT study performed at t Dosimetry calculations using a MLR model with a single SPECT/CT study are in good agreement with the standard protocol, while avoiding the use of dosimetry software and enabling improved patient comfort and reduced scanner and staff time.
Sections du résumé
BACKGROUND
BACKGROUND
Following each cycle of peptide receptor radionuclide therapy (PRRT), absorbed doses by tumors and normal organs are typically calculated from three quantitative single-photon emission computed tomography (SPECT)/computed tomography (CT) studies acquired at t
RESULTS
RESULTS
There was no difference in management decisions, whether PRRT can be safely continued or not because unsafe absorbed dose to risk organs between the standard and the MLR model-based protocol using a single SPECT/CT study performed at t
CONCLUSION
CONCLUSIONS
Dosimetry calculations using a MLR model with a single SPECT/CT study are in good agreement with the standard protocol, while avoiding the use of dosimetry software and enabling improved patient comfort and reduced scanner and staff time.
Identifiants
pubmed: 34436698
doi: 10.1186/s40658-021-00409-z
pii: 10.1186/s40658-021-00409-z
pmc: PMC8390741
doi:
Types de publication
Journal Article
Langues
eng
Pagination
63Informations de copyright
© 2021. The Author(s).
Références
J Clin Oncol. 2008 May 1;26(13):2124-30
pubmed: 18445841
Appl Radiat Isot. 2011 Jun;69(6):869-74
pubmed: 21419637
Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1847-56
pubmed: 18427807
Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):212-25
pubmed: 19727718
J Nucl Med. 2016 Jan;57(1):151-62
pubmed: 26471692
Eur J Nucl Med Mol Imaging. 2009 Jul;36(7):1138-46
pubmed: 19247653
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
EJNMMI Phys. 2018 Jun 19;5(1):10
pubmed: 29916115
BJR Case Rep. 2015 Aug 18;1(3):20150177
pubmed: 30363599
Ann Nucl Med. 2014 Jul;28(6):531-9
pubmed: 24687907
Acta Oncol. 2018 Apr;57(4):516-521
pubmed: 28920501
EJNMMI Phys. 2018 Dec 10;5(1):36
pubmed: 30535780
EJNMMI Phys. 2020 Jan 23;7(1):5
pubmed: 31975156
J Nucl Med. 2013 Jan;54(1):33-41
pubmed: 23223392
J Nucl Med. 2018 Jan;59(1):75-81
pubmed: 28588150
Appl Radiat Isot. 2001 Jul;55(1):89-96
pubmed: 11339536
Eur J Nucl Med Mol Imaging. 2011 Dec;38(12):2125-35
pubmed: 21892623
EJNMMI Phys. 2018 Dec 20;5(1):33
pubmed: 30569328
Ann Nucl Med. 2012 May;26(4):289-97
pubmed: 22222779
Eur J Nucl Med Mol Imaging. 2013 May;40(5):800-16
pubmed: 23389427
Acta Oncol. 2012 Jan;51(1):86-96
pubmed: 21961497
Cancer Imaging. 2011 Jun 15;11:56-66
pubmed: 21684829
Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1:S103-12
pubmed: 22388631
Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22
pubmed: 2032882
J Nucl Med. 2005 Jun;46(6):1023-7
pubmed: 15937315
J Nucl Med. 2007 Jan;48(1):134-42
pubmed: 17204710
J Nucl Med. 2009 Mar;50(3):477-84
pubmed: 19258258